Marshall Wace, LLP Akero Therapeutics, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $2.14 Million - $3.76 Million	120,674 New	120,674 $3.05 Million
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $27.3 Million - $34.6 Million	-662,523 Reduced 71.77%	260,535 $13.2 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $5.85 Million - $9.02 Million	-158,667 Reduced 14.67%	923,058 $43.1 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $15.7 Million - $21.2 Million	-421,639 Reduced 28.05%	1,081,725 $41.4 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $25.2 Million - $41.2 Million	752,524 Added 100.22%	1,503,364 $82.4 Million
Q3 2022 Nov 14, 2022	SELL	$10.15 - $34.05 $2.59 Million - $8.68 Million	-254,842 Reduced 25.34%	750,840 $25.6 Million
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $8.05 Million - $15.1 Million	1,005,682 New	1,005,682 $9.5 Million
Q1 2022 May 16, 2022	SELL	$12.97 - $22.26 $52,943 - $90,865	-4,082 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $81,109 - $107,111	4,082 New	4,082 $86,000
Q2 2020 Aug 13, 2020	SELL	$19.25 - $26.76 $89,782 - $124,808	-4,664 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$12.8 - $27.05 $59,699 - $126,161	4,664 New	4,664 $99,000

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.36B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.